ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2351

Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen-Induced Arthritis Via P38 MAPK and STAT3 Pathway

Xinyi Tang1 and Shengjun Wang2, 1Department of Laboratory Medicine, Jiangsu University Affi�liated People’s Hospital, Zhenjiang, China, 2Department of Laboratory Medicine, Jiangsu University Affiliated People’s Hospital, Zhenjiang, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, interleukins (IL) and rheumatoid arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose Helper T lymphocyte-17 (Th17) has recognized to be an important factor in rheumatoid arthritis (RA) pathogenesis. The natural ligand of glucocorticoid-induced tumor necrosis factor receptor (GITRL) could exacerbate autoimmune arthritis via the enhancement of Th17 cells expansion. It has reported that GITRL/GITR could trigger phosphorylation of p38 mitogen-activated protein kinase in T cell. The purpose of this study is to investigate the role of p38 signaling during the enhancement of Th17 expansion and exacerbation of autoimmune arthritis by GITRL stimulation.

Methods We used mouse GITRL (mGITRL) protein as a co-stimulatory factor for Th17 differentiation in presence or absence of p38 inhibitor and detected ability of Th17 differentiation. Activated naïve CD4+T cells were pretreated with or without p38 inhibitor before stimulated with mGITRL and phosphorylation of p38 and STAT3 were examined by western blot. And we injected mGITRL protein into collagen induced arthritis (CIA) mice alone or combine with the p38 inhibitor, and observed development of arthritis. 

Results In previous study, we have certificated a function of GITRL in exacerbating autoimmune arthritis via the enhancement of Th17 cells expansion. In this study, naïve CD4+T cells could differentiate into higher frequency of Th17 cells under the mGITRL co-stimulated and be attenuated in a concentration dependent manner by p38 inhibitor treatment. Also, the relative expression of RORγt and IL-17 mRNA was impaired with p38 inhibitor in a concentration dependent manner. Phosphorylation of p38 was reinforced in activated naïve CD4+T cells after stimulated with GITRL protein. STAT3 has two important phosphorylation sites, tyrosine705 (Tyr705) and serine727 (Ser727). An enhancement of STAT3Ser727 phosphorylation by mGITRL stimulate was observed and been attenuated in activated naïve CD4+T cells with p38 inhibitor pretreated. CIA models were established for investigate the function of p38 in the process of arthritis. Compared with the group treated by mGITRL protein (mGITRL-CIA group), the group injected with mGITRL and p38 inhibitor (mGITRL-SB203580-CIA group) had a later onset of symptoms and reached the peak score gently. There were more serious inflammatory changes in the mGITRL-CIA group. Th17 cells and the level of IL-17 in serum of the mGITRL-group increased significantly compared with the mGITRL-SB203580-CIA group. 

Conclusion Our results suggested that the enhancement of Th17 cells differentiation with mGITRL stimulation was influenced by p38-STAT3 singnaling pathway activation; the exacerbation of CIA development in mice by mGITRL can be released with p38 inhibitor treatment and correlate with the attenuation of Th17 cells. This phenomenon may provide a new insight in the study of RA pathopoiesis and clinical treatment.


Disclosure:

X. Tang,
None;

S. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ligand-of-glucocorticoid-induced-tumor-necrosis-factor-receptor-enhances-th17-cells-response-in-collagen-induced-arthritis-via-p38-mapk-and-stat3-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology